SCHEMBL7209007

SCHEMBL7209007

CCCCCCCCCCCCCCCCCC(C)CCO

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.57
LMNA P02545 5/20 0.52
ALDH1A1 P00352 2/20 0.50
OPRM1 P35372 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TSHR P16473 1/20 0.50
PRKD3 O94806 1/20 0.49
PRKCG P05129 1/20 0.49
PRKCB P05771 1/20 0.49
PRKCA P17252 1/20 0.49
PRKCH P24723 1/20 0.49
PRKCI P41743 1/20 0.49
PRKCE Q02156 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCZ Q05513 1/20 0.49
PRKCD Q05655 1/20 0.49
PRKD1 Q15139 1/20 0.49
SPHK1 Q9NYA1 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27498134 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL28744285 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL236012 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL1658183 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL3367737 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL22986838 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL1556084 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL3367475 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL20055710 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10
SCHEMBL5684486 1.00 ACE2 (0.57) ACE2LMNAALDH1A1OPRM1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613748-B2 C-glycosides having 2-amino groups; anticancer agents THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2003-09-02 US disclosed
US-20020128214-A1 C-glucosyl ether lipids RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128214-A1 C-glucosyl ether lipids UGCG, LIPC, UGGT1 ACE2 2159/4885LMNA 776/4885ALDH1A1 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.